Testing FL-091 PET scans for cancer detection
Part of Cancer clinical trials.
This study tests a new imaging agent called FL-091 to see if it helps doctors find and stage cancers like head and neck, colorectal, or pancreatic cancer. You’ll get a PET scan that may give clearer pictures of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a suspected or confirmed cancer (like head and neck, colorectal, or pancreatic cancer) or you are a healthy volunteer
- You can lie still for a PET scan and are not claustrophobic or afraid of radiation
- You are not pregnant or breastfeeding, and if you could become pregnant, you use birth control
- You have no known allergies to the study imaging agent, and your fasting blood sugar is not too high
- You are willing and able to follow the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent (68Ga-FL-031) to see if it can help find and stage tumors in people with small cell lung cancer, breast cancer, nasopharyngeal cancer, or other cancers. The goal is to improve diagnosis and treatment planning.
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
This trial tests a new radioactive tracer called 68Ga-SFB6-ZN01 for PET/CT scans in people with suspected or confirmed solid tumors. It aims to see if this tracer can help find cancer or detect recurrence after treatment.
This study uses a special imaging agent that targets a protein called FAP found on many solid tumors. It helps doctors see tumors more clearly and stage them better. If you have a confirmed solid tumor and are able to undergo PET or SPECT/CT scans, this trial may help improve how your cancer is evaluated.
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
Hear when a new Malignant Tumors With Positive NTSR1 Expression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.